




Figure 1a. The Structures of Isovaleramide and Related Compounds.




2-methyl
isovaleramide




3-methyl
isovaleramide




2,2-dimethyl
isovaleramide




2,3-dimethyl
isovaleramide




4-methyl
isovaleramide




2,4-dimethyl
isovaleramide




3,4-dimethyl
isovaleramide




2,2,4-trimethyl
isovaleramide




3-hydroxy
isovaleramide




4-hydroxy
isovaleramide




4-hydroxy-
3-methyl
isovaleramide




N-(2-acetamido)
isovaleramide




2-hydroxyl
isovaleramide




2-methyl-1-propyl
sulfonamide




1-methylethyl
sulfamate



2-methyl-1-propyl
sulfamate



Isopropyl
carbamate



Isobutyl carbamate

Figure 1b: Structures of compounds structurally related to isovaleramide

Figure 2:

**NPS 1776 Formulation II (Coated 400 mg Tablet)
Clinical Batch Dissolution in SGF only (n=1), SIF only (n=1), and 2 Stage Media (n=6)**




Figure 3.

NPS 1776 Formulation III (Coated 600 mg Tablet)
Development Batch Dissolution in SGF only (n=1), SIF only (n=1), and 2 Stage Media (n=2)




Figure 4. NPS 1776 Release From Coated MPC Formulations




Figure 5. NPS 1776 Release From Coated MPC Formulations

